Colistin (Coly-Mycin)

Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.

Also Known As:

Networked: 942 relevant articles (123 outcomes, 139 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Li, Jian: 46 articles (12/2015 - 05/2003)
2.	Nation, Roger L: 40 articles (12/2015 - 05/2003)
3.	Falagas, Matthew E: 22 articles (01/2014 - 01/2005)
4.	Michalopoulos, Argyris: 12 articles (05/2011 - 01/2005)
5.	Kasiakou, Sofia K: 10 articles (06/2006 - 01/2005)
6.	Giamarellou, Helen: 9 articles (12/2015 - 11/2002)
7.	Rolain, Jean-Marc: 9 articles (03/2015 - 01/2008)
8.	Falagas, M E: 9 articles (02/2014 - 02/2005)
9.	Couet, William: 8 articles (02/2015 - 08/2010)
10.	Turnidge, John D: 7 articles (12/2015 - 05/2003)

Related Diseases

1.	Infection 08/01/2014 - "The purpose of this investigation was to compare the efficacy of colistin-based therapies in extremely drug-resistant Acinetobacter spp. bloodstream infections (XDR-ABSI). " 03/01/2015 - "Based on the above assessments, the quality of evidence presented for each outcome ranged from "very low" to "low." A significant improvement in clinical response (odds ratio, 1.57; 95% CI, 1.14-2.15; p = 0.006; I2 = 37%), microbiological eradication (odds ratio, 1.61; 95% CI, 1.11-2.35; p = 0.01; I2 = 0%), and infection-related mortality (odds ratio, 0.58; 95% CI, 0.34-0.96; p = 0.04; I2 = 46%) was observed with the addition of aerosolized colistin to i.v. treatment, whereas the addition of aerosolized colistin did not affect overall mortality (odds ratio, 0.74; 95% CI, 0.54-1.01; p = 0.06; I2 = 25%) or nephrotoxicity (odds ratio, 1.18; 95% CI, 0.76-1.83; p = 0.45; I2 = 0%). " 10/01/2014 - "We report three cases of external ventricular derivation infections caused by multidrug-resistant Gram-negative rods and treated successfully with intraventricular colistin. " 06/01/2014 - "No statistically significant differences were observed between patients who achieved and failed to achieve bacterial cure with regards to age, gender, site of infection, mg/kg dose or duration of colistin use. " 12/01/2015 - "Colistin was substantially less effective in lung infection. "
2.	Pneumonia (Pneumonitis) 12/01/2004 - "Successful therapy of carbapenem-resistant Acinetobacter baumannii strains has been reported with colistin, but recently we argued against its use as monotherapy because of the poor results obtained in a mouse pneumonia model. " 08/01/2003 - "Colistin did not lead to good results in a mouse pneumonia model. " 11/01/2010 - "In conclusion, inhaled colistin was effective and safe for the treatment of two children with tracheobronchitis, and one child with necrotizing pneumonia. " 01/01/2011 - "A retrospective observational study on the efficacy of colistin by inhalation as compared to parenteral administration for the treatment of nosocomial pneumonia associated with multidrug-resistant Pseudomonas aeruginosa." 09/01/2009 - ": To study the efficacy of intratracheal colistin sulfate therapy in a murine model of acute pneumonia caused by a clinical CRAB strain, Ab396. "
3.	Ventilator-Associated Pneumonia (Pneumonia, Ventilator Associated) 12/01/2012 - "In this study we aimed to assess the safety and efficacy of high-dose IV colistin (COL) and aerosolized COL for the treatment of Acinetobacter baumannii ventilator-associated pneumonia (VAP). " 12/01/2012 - "Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii." 08/01/2007 - "Colistin-susceptible ventilator-associated pneumonia episodes can be effectively treated using colistin without significant renal dysfunction. " 03/01/2015 - "Based on the present results and awaiting further evidence from randomized trials, aerosolized colistin is associated with improved outcome in the treatment of ventilator-associated pneumonia although the level of evidence was low." 12/01/2012 - "The aim of the study was to assess efficacy of nebulized colistin for treating ventilator-associated pneumonia (VAP) caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. "
4.	Critical Illness (Critically Ill) 12/01/2010 - "Although the pharmacodynamic parameters that better predict the efficacy of colistin are not known in humans, in critically ill adult patients the IV administration of CMS 2 million International Units (174 mg) q8h results in apparently suboptimal plasma concentrations of colistin, which is undetectable in BAL. " 08/01/2015 - "The present study has demonstrated that the addition of inhaled colistin to IV colistin led to a shorter TBE in critically ill children with VAP due to COS GNB. " 12/01/2014 - "In this study, CMS and colistin concentrations were measured on two separate occasions within the plasma and epithelial lining fluid (ELF) of critically ill patients (n = 12) who had received 2 million international units (MIU) of CMS by aerosol delivery and then intravenous administration. " 07/01/2014 - "Our study showed that high-dose, extended-interval colistin can be given to critically ill patients without any significant risk of nephrotoxicity." 08/01/2013 - "The objective was to study the PK/PD differences of CMS and colistin between three different CMS dosage regimens in the same critically ill patient. "
5.	Sepsis (Septicemia) 08/01/2015 - "Safety and Efficacy of Intravenous Colistin in Neonates With Culture Proven Sepsis." 08/01/2015 - "We present our experience of efficacy and safety of intravenous colistin in the treatment of sepsis in term and preterm neonates. " 03/01/2015 - "Antimicrobial therapy for sepsis caused by carbapenem- and colistin-resistant Klebsiella pneumoniae is not well established. " 01/01/2015 - "The significant variability of pharmacokinetic parameters of colistin was established both in patients with septicemia and in control group. " 12/01/2014 - "Efficacy and safety of intravenous colistin in preterm infants with nosocomial sepsis caused by Acinetobacter baumannii."

Related Drugs and Biologics

1.	Rifampin (Rifampicin)
2.	Tobramycin (Nebcin)
3.	Anti-Bacterial Agents (Antibiotics)
4.	Sulbactam
5.	tigecycline (Tygacil)
6.	Imipenem
7.	Colistin (Coly-Mycin)
8.	Amikacin (A.M.K)
9.	Amphotericin B (Amphotericin)
10.	Cefotaxime (Kendrick)

Related Therapies and Procedures

1.	Intensive Care (Surgical Intensive Care)
2.	Artificial Respiration (Mechanical Ventilation)
3.	Catheters
4.	Arthroplasty
5.	Oral Administration